{"altmetric_id":6043900,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":5},"twitter":{"unique_users_count":4,"unique_users":["sejadiMD","johnrbrum","OncologyTimes","ellenscharaga"],"posts_count":4},"facebook":{"unique_users_count":1,"unique_users":["100342973965"],"posts_count":1}},"selected_quotes":["One of our most viewed articles: Treatment Challenges of Neuroendocrine Prostate Cancer","The treatment challenges of aggressive neuroendocrine #prostatecancer."],"citation":{"altmetric_jid":"4f6fa5ea3cf058f610005bde","authors":["Carlson, Robert H."],"doi":"10.1097\/01.cot.0000461860.84751.a3","first_seen_on":"2016-03-03T03:32:59+00:00","issns":["0276-2234"],"issue":"4","journal":"Oncology times","last_mentioned_on":1459519084,"links":["http:\/\/journals.lww.com\/oncology-times\/Fulltext\/2015\/02250\/The_Treatment_Challenges_of_Neuroendocrine.3.aspx?WT.mc_id=HPxADx20100319xMP"],"pdf_url":"http:\/\/pdfs.journals.lww.com\/oncology-times\/2015\/02250\/The_Treatment_Challenges_of_Neuroendocrine.3.pdf","pubdate":"2015-02-25T00:00:00+00:00","startpage":"1","title":"The Treatment Challenges of Neuroendocrine Prostate Cancer","type":"article","uri":"http:\/\/journals.lww.com\/oncology-times\/Fulltext\/2015\/02250\/The_Treatment_Challenges_of_Neuroendocrine.3.aspx","volume":"37"},"altmetric_score":{"score":2.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":2.5},"context_for_score":{"all":{"total_number_of_other_articles":7474500,"mean":6.4836868429538,"rank":2909706,"this_scored_higher_than_pct":60,"this_scored_higher_than":4510343,"rank_type":"exact","sample_size":7474500,"percentile":60},"similar_age_3m":{"total_number_of_other_articles":282326,"mean":10.721281338882,"rank":101308,"this_scored_higher_than_pct":63,"this_scored_higher_than":178469,"rank_type":"exact","sample_size":282326,"percentile":63},"this_journal":{"total_number_of_other_articles":1692,"mean":4.3734169130692,"rank":831,"this_scored_higher_than_pct":50,"this_scored_higher_than":853,"rank_type":"exact","sample_size":1692,"percentile":50},"similar_age_this_journal_3m":{"total_number_of_other_articles":115,"mean":4.2564035087719,"rank":62,"this_scored_higher_than_pct":46,"this_scored_higher_than":53,"rank_type":"exact","sample_size":115,"percentile":46}}},"demographics":{"poster_types":{"member_of_the_public":2,"practitioner":2},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":2,"Members of the public":2}}},"geo":{"twitter":{"GB":1,"US":2}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/sejadiMD\/statuses\/705231998504169473","license":"gnip","citation_ids":[6043900],"posted_on":"2016-03-03T03:23:05+00:00","author":{"name":"Samuel Ejadi, MD","image":"https:\/\/pbs.twimg.com\/profile_images\/508415747467382784\/uQtyO3yu_normal.jpeg","description":"Medical Oncologist \u25aa Immunology \u25aa Cancer Immunotherapy \u25aa ImmunoOncology \u25aa Nutrition \u25aa Environment \u25aa Conscience \u25aa\n OncologyScience Think Tank","id_on_source":"sejadiMD","tweeter_id":"937376640","geo":{"lt":null,"ln":null},"followers":304},"tweet_id":"705231998504169473"},{"url":"http:\/\/twitter.com\/johnrbrum\/statuses\/705290946175475712","license":"gnip","rt":["sejadiMD"],"citation_ids":[6043900],"posted_on":"2016-03-03T07:17:19+00:00","author":{"name":"John R Brum","image":"https:\/\/pbs.twimg.com\/profile_images\/845166985923084289\/I9o6XirZ_normal.jpg","description":"Supporter of all Medical Research & Medical Charities | #CR_UK | #BreastCancer | #ProstateCancer | #MaleBreastCancer | #BowelCancer | #CancerSurvivor |","id_on_source":"johnrbrum","tweeter_id":"3367140725","geo":{"lt":50.77141,"ln":0.10268,"country":"GB"},"followers":460},"tweet_id":"705290946175475712"},{"url":"http:\/\/twitter.com\/OncologyTimes\/statuses\/715900339296329728","license":"gnip","citation_ids":[6043900],"posted_on":"2016-04-01T13:55:16+00:00","author":{"name":"Oncology Times","url":"http:\/\/oncology-times.com","image":"https:\/\/pbs.twimg.com\/profile_images\/755059964738101251\/0uHShr24_normal.jpg","description":"Reporting essential clinical news w\/ independent analysis for cancer care professionals to optimize patient care & outcomes; oncology\/hematology","id_on_source":"OncologyTimes","tweeter_id":"19495715","geo":{"lt":40.71427,"ln":-74.00597,"country":"US"},"followers":34048},"tweet_id":"715900339296329728"},{"url":"http:\/\/twitter.com\/ellenscharaga\/statuses\/715901043234705408","license":"gnip","rt":["OncologyTimes"],"citation_ids":[6043900],"posted_on":"2016-04-01T13:58:04+00:00","author":{"name":"Ellen Scharaga","url":"https:\/\/about.me\/ellenscharaga","image":"https:\/\/pbs.twimg.com\/profile_images\/1222081098\/Ellen_Scharaga_normal.jpg","description":"OncoMed Pharmaceutical Services\u2019 Ellen Scharaga manages the Oncology Pharmacy Services division as a Senior Vice President.","id_on_source":"ellenscharaga","tweeter_id":"228097334","geo":{"lt":40.80066,"ln":-73.72846,"country":"US"},"followers":92},"tweet_id":"715901043234705408"}],"facebook":[{"title":"The Treatment Challenges of Neuroendocrine Prostate Cancer : Oncology Times","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=10154106316163966&id=100342973965","license":"public","citation_ids":[6043900],"posted_on":"2016-04-01T13:52:59+00:00","summary":"Read one of Oncology Times' most viewed articles and learn more about this often-overlooked disease.","author":{"name":"Oncology Times","url":"https:\/\/www.facebook.com\/100342973965","facebook_wall_name":"Oncology Times","image":"https:\/\/graph.facebook.com\/100342973965\/picture","id_on_source":"100342973965"}}]}}